A Personal View published in The Lancet Oncology challenges the long-standing perception of metastatic brain cancer, calling ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Retinal thickness could be an early indicator of diseases such as Type 2 diabetes and dementia, according to study by a team ...

The central nervous system (CNS), composed of the brain ... provides few treatment options for patients with CNS injuries or diseases. With only pharmacological treatments available that delay ...

Multiple sclerosis, often shortened to 'MS', is a long-lasting chronic disease of the central nervous system. There is ...

Using AI, researchers created detailed retinal maps, identifying genetic factors influencing thickness and potential biomarkers for disease detection.

The development of drugs to treat major diseases of the central nervous system relies in part on the development of novel strategies to cross the blood brain barrier. Michel Khrestchatisky and ...

ZURICH and NESS ZIONA, Israel - NLS Pharmaceutics Ltd. (Nasdaq: NLSP) and Kadimastem Ltd. (TASE: KDST) announced plans for a merger, aiming to enhance diabetes treatment by combining their expertise ...

In mice with Alzheimer's, the course of menthol for a six-month-long period was enough to stop the cognitive abilities and memory capabilities of the mice from deteriorating. In addition, it appears ...